Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats undergoing catch-up growth

Gu,Chengying; Zeng,Yipeng; Tang,Zhaosheng; Wang,Chaoxun; He,Yanju; Feng,Xinge; Zhou,Ligang

doi:10.3892/mmr.2015.4245

Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats undergoing catch-up growth

Authors:
- Chengying Gu
- Yipeng Zeng
- Zhaosheng Tang
- Chaoxun Wang
- Yanju He
- Xinge Feng
- Ligang Zhou
View Affiliations

Affiliations: Department of Endocrinology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China, Department of Traditional Chinese Medicine, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai 201399, P.R. China, Department of Endocrinology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China
Published online on: August 25, 2015 https://doi.org/10.3892/mmr.2015.4245
Pages: 6451-6460
Copyright: © Gu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study investigated the effects of Astragalus polysaccharides (APS) on insulin resistance by modulation of hepatic sirtuin 1 (SIRT1)‑peroxisome proliferator‑activated receptor (PPAR)‑γ coactivator (PGC)‑1α/PPARα‑fibroblast growth factor (FGF)21, and glucose and lipid metabolism. Thirty male Sprague Dawley rats were divided into three groups: A normal control group, a catch‑up growth group and an APS‑treated (APS-G) group. The latter two groups underwent food restriction for 4 weeks, prior to being provided with a high fat diet, which was available ad libitum. The APS‑G group was orally treated with APS for 8 weeks, whereas the other groups were administered saline. Body weight was measured and an oral glucose tolerance test (OGTT) was conducted after 8 weeks. The plasma glucose and insulin levels obtained from the OGTT were assayed, and hepatic morphology was observed by light and transmission electron microscopy. In addition, the mRNA expression levels of PGC‑1α/PPARα, and the protein expression levels of SIRT1, FGF21 and nuclear factor‑κB were quantified in the liver and serum. APS treatment suppressed abnormal glycolipid metabolism and insulin resistance following 8 weeks of catch‑up growth by improving hepatic SIRT1‑PPARα‑FGF21 intracellular signaling and reducing chronic inflammation, and by partially attenuating hepatic steatosis. The suppressive effects of APS on liver acetylation and glycolipid metabolism‑associated molecules contributed to the observed suppression of insulin resistance. However, the mechanism underlying the effects of APS on insulin resistance requires further research in order to be elucidated. Rapid and long‑term treatment with APS may provide a novel, safe and effective therapeutic strategy for type 2 diabetes.

View Figures

View References

1	Prader A, Tanner JM and von Harnack GA: Catch-up growth following illness or starvation. An example of developmental canalization in man. Pediatrics. 62:646–659. 1963. View Article : Google Scholar
2	Chen LL: Catch-up growth - a new territory for understanding insulin resistance. Chin J Endocrinol Metab. 24:235–238. 2008.
3	Xiao XH, Zhang ZX, Cohen HJ, Wang H, Li W, Wang T, Xu T, Liu A, Gai MY, Ying S, et al: Evidence of a relationship between infant birth weight and later diabetes and impaired glucose regulation in a Chinese population. Diabetes Care. 31:483–487. 2008. View Article : Google Scholar
4	Fu Q, McKnight RA, Yu X, Wang L, Callaway CW and Lane RH: Uteroplacental insufficiency induces site-specific changes in histone H3 covalent modifications and affects DNA-histone H3 positioning in day0 IUGR rat liver. Physiol Genomics. 20:108–116. 2004. View Article : Google Scholar : PubMed/NCBI
5	Lane RH, MacLennan NK, Hsu JL, Janke SM and Pham TD: Increased hepatic peroxisome proliferator-activated receptor-gamma coactivator-1 gene expression in a rat model of intrauterine growth retardation and subsequent insulin resistance. Endocrinology. 143:2486–2490. 2002.PubMed/NCBI
6	Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, Adelmant G, Stafford J, Kahn CR, Granner DK, et al: Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-l. Nature. 413:131–138. 2001. View Article : Google Scholar : PubMed/NCBI
7	Yeung F, Hoberg JE, Ramsey CS, Keller MD, Jones DR, Frye RA and Mayo MW: Modulation of NF-kappa B-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 23:2369–2380. 2004. View Article : Google Scholar : PubMed/NCBI
8	Nannipieri M, Gonzales C, Baldi S, Posadas R, Williams K, Haffner SM, Stern MP and Ferrannini E; Mexico City diabetes study: Liver enzymes, the metabolic syndrome and incident diabetes: The Mexico City diabetes study. Diabetes Care. 28:1757–1762. 2005. View Article : Google Scholar : PubMed/NCBI
9	Cettour-Rose P, Samec S, Russell AP, Summermatter S, Mainieri D, Carrillo-Theander C, Montani JP, Seydoux J, Rohner-Jeanrenaud F and Dulloo AG: Redistribution of glucose from skeletal muscle to adipose tissue during catch-up fat: A link between catch-up growth and later metabolic syndrome. Diabetes. 54:751–756. 2005. View Article : Google Scholar : PubMed/NCBI
10	Chen R, Shao H, Lin S, Zhang JJ and Xu KQ: Treatment with Astragalus membranaceus produces antioxidative effects and attenuates intestinal mucosa injury induced by intesti-nalischemia-reperfusion in rats. Am J Chin Med. 39:879–887. 2011. View Article : Google Scholar
11	Sang Z, Zhou L, Fan X and McCrimmon RJ: Radix astragali (huangqi) as a treatment for defective hypoglycemia counter-regulation in diabetes. Am J Chin Med. 38:1027–1038. 2010. View Article : Google Scholar
12	Chen W, Xia Y, Zhao X, Wang H, Chen W, Yu M, Li Y, Ye H and Zhang Y: The critical role of Astragalus polysaccharides for the improvement of PPARα [correction of PPRAα]-mediated lipotoxicity in diabetic cardiomyopathy. PLoS One. 7:e455412012. View Article : Google Scholar
13	Magee TR, Han G, Cherian B, Khorram O, Ross MG and Desai M: Down-regulation of transcription factor peroxisome proliferator-activated receptor in programmed hepatic lipid dysregulation and inflammation in intrauterine growth-restricted offspring. Am J Obstet Gynecol. 199:271 el–5. 2008. View Article : Google Scholar
14	Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, Badman MK, Martinez-Chantar ML and Maratos-Flier E: Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 139:456–463. 2010. View Article : Google Scholar : PubMed/NCBI
15	Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, et al: Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol. 53:934–940. 2010. View Article : Google Scholar : PubMed/NCBI
16	Leibiger IB and Berggren PO: Sirt1: A metabilic a master switch that modulates lifespan. Nat Med. 12:34–36. 2006. View Article : Google Scholar
17	Gerhart-Hines Z, Rodgers JT, Bare O, Lerin C, Kim SH, Mostoslavsky R, Alt FW, Wu Z and Puigserver P: Metabolic control of muscle mitochondrial function and fatty acid oxidation through SIRT1/PGC-1 alpha. Embo J. 26:1913–1923. 2007. View Article : Google Scholar : PubMed/NCBI
18	Picard F, Kurtev M, Chung N, Topark-Ngarm A, Senawong T, Machado De Oliveira R, Leid M, McBurney MW and Guarente L: Sirt1 promotes fat mobilization in white adpecytes by repressing PPAR-gamma. Nature. 429:771–776. 2004. View Article : Google Scholar : PubMed/NCBI
19	Ma L, Dong W, Wang R, Li Y, Xu B, Zhang J, Zhao Z and Wang Y: Effect of caloric restriction on the SIRT1/mTOR signaling pathways in senile mice. Brain Res Bull. 116:67–72. 2015. View Article : Google Scholar : PubMed/NCBI
20	Zhao Y, Ling F, Griffin TM, He T, Towner R, Ruan H and Sun XH: Up-regulation of the Sirtuin 1 (Sirt1) and peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) genes in white adipose tissue of Id1 protein-deficient mice: Implications in the protection against diet and age-induced glucose intolerance. J Biol Chem. 289:29112–29122. 2014. View Article : Google Scholar : PubMed/NCBI
21	Lee J, Hong SW, Park SE, Rhee EJ, Park CY, Oh KW, Park SW and Lee WY: Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis. Metabolism. 63:1041–1048. 2014. View Article : Google Scholar : PubMed/NCBI
22	Estall JL, Ruas JL, Choi CS, Laznik D, Badman M, Maratos-Flier E, Shulman GI and Spiegelman BM: PGC-1α negatively regulates hepatic FGF21 expression by modulating the heme/Rev-Erbα axis. Proc Natl Acad Sci USA. 106:22510–22515. 2009. View Article : Google Scholar
23	Yu D, Sun CY, Sun GP, Ren GP, Ye XL, Zhu SL, Wang WF, Xu PF, Li SJ, Wu Q, et al: The synergistic effect of FGF-21 and insulin on regulating glucose metabolism and its mechanism. Yao Xue Xue Bao. 49:977–984. 2014.in Chinese. PubMed/NCBI
24	Ge X, Chen C, Hui X, Wang Y, Lam KS and Xu A: Fibroblast growth factor 21 induces glucose transporter-1 expression through activation of the serum response factor/Ets-like protein-1 in adipocytes. J Biol Chem. 286:34533–34541. 2011. View Article : Google Scholar : PubMed/NCBI
25	Li L, Hai J, Li Z, Zhang Y, Peng H, Li K and Weng X: Resveratrol modulates autophagy and NF-κB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 63:166–173. 2013. View Article : Google Scholar
26	Gariani K, Philippe J and Jornayvaz FR: Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside. Diabetes Metab. 39:16–26. 2013. View Article : Google Scholar
27	Wu F and Chen X: A review of pharmacological study on Astragalus membranaceus (Fisch) Bge. Zhong Yao Cai. 27:232–234. 2004.In Chinese. PubMed/NCBI
28	Lu J, Chen X, Zhang Y, Xu J, Zhang L, Li Z, Liu W, Ouyang J, Han S and He X: Astragalus polysaccharide induces anti-inflammatory effects dependent on AMPK activity in palmitate-treated RAW264.7 cells. Int J Mol Med. 31:1463–1470. 2013.PubMed/NCBI
29	He X, Shu J, Xu L, Lu C and Lu A: Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1β production in THP-1 cells. Molecules. 17:3155–3164. 2012. View Article : Google Scholar : PubMed/NCBI
30	Li XT, Zhang YK, Kuang HX, Jin FX, Liu DW, Gao MB, Liu Z and Xin XJ: Mitochondrial protection and anti-aging activity of astragalus polysaccharides and their potential mechanism. Int J Mol Sci. 13:1747–1761. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wang LX and Han ZW: The effect of astragalus polysaccharide on endotoxin-induced toxicity in mice. Yao Xue Xue Bao. 27:5–9. 1992.In Chinese.
32	Wang N, Zhang D, Mao X, Zou F, Jin H and Ouyang J: Astragalus polysaccharides decreased the expression of PTP1B through relieving ER stress-induced activation of ATF6 in a rat model of type 2 diabetes. Mol Cell Endocrinol. 307:89–98. 2009. View Article : Google Scholar : PubMed/NCBI
33	Mao XQ, Wu Y, Wu K, Liu M, Zhang JF, Zou F and Ou-Yang JP: Astragalus polysaccharide reduces hepatic endoplasmic reticulum stress and restores glucose homeostasis in a diabetic KKAy mouse model. Acta Pharmacol Sin. 28:1947–1956. 2007. View Article : Google Scholar : PubMed/NCBI
34	Chen W, Chen WJ, Xia YP, Lu Y and Yu MH: Effects of astragalus polysaccharides on lipid metabolism and PPAR-α gene expression in myocardium of diabetic hamsters. Fudan Univ J Med Sci. 37:194–197. 2010.
35	Caton PW, Holness MJ, Bishop-Bailey D and Sugden MC: PPAR α-LXR as a novel metabolostatic signalling axis in skeletal muscle that acts to optimize substrate selection in response to nutrient status. Biochem J. 437:521–530. 2011. View Article : Google Scholar : PubMed/NCBI
36	Zou F, Mao XQ, Wang N, Liu J and Ou-Yang JP: Astragalus polysaccharides alleviates glucose toxicity and restores glucose homeostasis in diabetic states via activation of AMPK. Acta Pharmacol Sin. 30:1607–1615. 2009. View Article : Google Scholar : PubMed/NCBI